A 12-week, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster 100/6 (Beclomethasone Dipropionate 100 ug Plus Formoterol 6 ug/Actuation), 2 Puffs b.i.d., Versus Symbicort 200/6 (Budesonide 200 ug Plus Formoterol 6 ug/Actuation), 2 Inhalations b.i.d., on Parameters of Small Airway Function in Patients With Chronic Obstructive Pulmonary Disease.

Trial Profile

A 12-week, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster 100/6 (Beclomethasone Dipropionate 100 ug Plus Formoterol 6 ug/Actuation), 2 Puffs b.i.d., Versus Symbicort 200/6 (Budesonide 200 ug Plus Formoterol 6 ug/Actuation), 2 Inhalations b.i.d., on Parameters of Small Airway Function in Patients With Chronic Obstructive Pulmonary Disease.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Budesonide/formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms Fair
  • Most Recent Events

    • 10 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Nov 2012 Planned number of patients changed from 144 to 170 as reported by European Clinical Trials Database.
    • 06 Jun 2012 Planned End Date changed from 1 Jan 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top